Real-world treatment duration in patients with non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion (EGFRex20ins) mutations receiving mobocertinib through the global Expanded Access Program (EAP)

被引：1

作者：

Lee, V. H. F. ^{[1
]}

Lin, M. ^{[2
]}

Curran, E. ^{[2
]}

Yin, Y. ^{[2
]}

Churchill, E. ^{[2
]}

Allen, S. ^{[2
]}

Abovich, J. ^{[2
]}

Leighl, N. ^{[3
]}

机构：

[1] Univ Hong Kong, Dept Clin Oncol, Li Ka Shing Fac Med, Hong Kong, Peoples R China

[2] Takeda Dev Ctr Amer Inc, Global Evidence & Outcomes Res, Lexington, MA USA

[3] Princess Margaret Canc Ctr, Dept Med Oncol & Hematol, Toronto, ON, Canada

来源：

关键词：

D O I：

10.1016/j.annonc.2022.07.1236

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

111P

引用

页码：S1059 / S1059

页数：1